These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 36165893)

  • 1. Stromal Reprogramming by FAK Inhibition Overcomes Radiation Resistance to Allow for Immune Priming and Response to Checkpoint Blockade.
    Lander VE; Belle JI; Kingston NL; Herndon JM; Hogg GD; Liu X; Kang LI; Knolhoff BL; Bogner SJ; Baer JM; Zuo C; Borcherding NC; Lander DP; Mpoy C; Scott J; Zahner M; Rogers BE; Schwarz JK; Kim H; DeNardo DG
    Cancer Discov; 2022 Dec; 12(12):2774-2799. PubMed ID: 36165893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells.
    Osipov A; Blair AB; Liberto J; Wang J; Li K; Herbst B; Xu Y; Li S; Niu N; Rashid R; Ding D; Liu Y; Wang Z; Wolfgang CL; Burkhart RA; Laheru D; Zheng L
    Cancer Biol Med; 2021 Feb; 18(1):206-214. PubMed ID: 33628595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
    Jiang H; Hegde S; Knolhoff BL; Zhu Y; Herndon JM; Meyer MA; Nywening TM; Hawkins WG; Shapiro IM; Weaver DT; Pachter JA; Wang-Gillam A; DeNardo DG
    Nat Med; 2016 Aug; 22(8):851-60. PubMed ID: 27376576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer.
    Canel M; Sławińska AD; Lonergan DW; Kallor AA; Upstill-Goddard R; Davidson C; von Kriegsheim A; Biankin AV; Byron A; Alfaro J; Serrels A
    Gut; 2023 Dec; 73(1):131-155. PubMed ID: 36977556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1.
    Zhang Z; Song B; Wei H; Liu Y; Zhang W; Yang Y; Sun B
    Drug Resist Updat; 2024 Mar; 73():101040. PubMed ID: 38228036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro.
    Mohamed AA; Thomsen A; Follo M; Zamboglou C; Bronsert P; Mostafa H; Amen A; Mekawy M; Grosu AL; Brunner TB
    Strahlenther Onkol; 2021 Jan; 197(1):27-38. PubMed ID: 32705304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion.
    Jiang H; Liu X; Knolhoff BL; Hegde S; Lee KB; Jiang H; Fields RC; Pachter JA; Lim KH; DeNardo DG
    Gut; 2020 Jan; 69(1):122-132. PubMed ID: 31076405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy.
    Principe DR; Narbutis M; Kumar S; Park A; Viswakarma N; Dorman MJ; Kamath SD; Grippo PJ; Fishel ML; Hwang RF; Thummuri D; Underwood PW; Munshi HG; Trevino JG; Rana A
    Cancer Res; 2020 Aug; 80(15):3101-3115. PubMed ID: 32238357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma.
    Le Large TYS; Bijlsma MF; El Hassouni B; Mantini G; Lagerweij T; Henneman AA; Funel N; Kok B; Pham TV; de Haas R; Morelli L; Knol JC; Piersma SR; Kazemier G; van Laarhoven HWM; Giovannetti E; Jimenez CR
    J Exp Clin Cancer Res; 2021 Mar; 40(1):91. PubMed ID: 33750427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focal Adhesion Kinase: A promising therapeutic target in pancreatic adenocarcinoma.
    Decaup E; Rochotte J; Pyronnet S; Bousquet C; Jean C
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):246-248. PubMed ID: 27939096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.
    Begum A; Ewachiw T; Jung C; Huang A; Norberg KJ; Marchionni L; McMillan R; Penchev V; Rajeshkumar NV; Maitra A; Wood L; Wang C; Wolfgang C; DeJesus-Acosta A; Laheru D; Shapiro IM; Padval M; Pachter JA; Weaver DT; Rasheed ZA; Matsui W
    PLoS One; 2017; 12(7):e0180181. PubMed ID: 28692661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer.
    Fujiwara K; Saung MT; Jing H; Herbst B; Zarecki M; Muth S; Wu A; Bigelow E; Chen L; Li K; Jurcak N; Blair AB; Ding D; Wichroski M; Blum J; Cheadle N; Koenitzer J; Zheng L
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32675194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the therapeutic potential of focal adhesion kinase inhibition in overcoming chemoresistance in pancreatic ductal adenocarcinoma.
    Scianò F; Terrana F; Pecoraro C; Parrino B; Cascioferro S; Diana P; Giovannetti E; Carbone D
    Future Med Chem; 2024 Feb; 16(3):271-289. PubMed ID: 38269431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanodrug-bacteria conjugates-mediated oncogenic collagen depletion enhances immune checkpoint blockade therapy against pancreatic cancer.
    Li Z; Mo F; Guo K; Ren S; Wang Y; Chen Y; Schwartz PB; Richmond N; Liu F; Ronnekleiv-Kelly SM; Hu Q
    Med; 2024 Apr; 5(4):348-367.e7. PubMed ID: 38521069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
    Huang J; Chen P; Liu K; Liu J; Zhou B; Wu R; Peng Q; Liu ZX; Li C; Kroemer G; Lotze M; Zeh H; Kang R; Tang D
    Gut; 2021 May; 70(5):890-899. PubMed ID: 32816920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer.
    Mehra S; Garrido VT; Dosch AR; Lamichhane P; Srinivasan S; Singh SP; Zhou Z; De Castro Silva I; Joshi C; Ban Y; Datta J; Gilboa E; Merchant NB; Nagathihalli NS
    Cancer Res Commun; 2023 Jul; 3(7):1224-1236. PubMed ID: 37448553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
    Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma.
    Wang J; Saung MT; Li K; Fu J; Fujiwara K; Niu N; Muth S; Wang J; Xu Y; Rozich N; Zlomke H; Chen S; Espinoza B; Henderson M; Funes V; Herbst B; Ding D; Twyman-Saint Victor C; Zhao Q; Narang A; He J; Zheng L
    J Exp Med; 2022 May; 219(5):. PubMed ID: 35404390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focal adhesion kinase priming in pancreatic cancer, altering biomechanics to improve chemotherapy.
    Murphy KJ; Zhu J; Trpceski M; Pereira BA; Timpson P; Herrmann D
    Biochem Soc Trans; 2022 Aug; 50(4):1129-1141. PubMed ID: 35929603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.